共 50 条
- [7] Impact of risankizumab on achieving minimal clinically important differences in patient-reported disease activity, fatigue, and pain among patients with active psoriatic arthritis: Analysis of 2 phase 3 clinical trials [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB68 - AB68
- [8] Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis [J]. RMD OPEN, 2016, 2 (02):